marked.bio

Company

Genmab

3 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 2 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

rinatabart sesutecan 3bevacizumab 3pembrolizumab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

3 of 3 trials shown

  1. Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

    Recruiting Phase 3 Genmab Started 2026Primary completion 2029-12 NCT07564141

    rinatabart sesutecanbevacizumab FDA EUcarboplatingemcitabinepaclitaxelpegylated liposomal doxorubicin

    …cizumab) is required for participants with breast cancer susceptibility gene (BRCA 1- and BRCA 2)-mutated (germline or somatic) or homologous recombination deficiency (HRD)-positive disease.

    BRCA1/2 mutationPlatinum-Sensitive Ovarian Cancer, Ovarian Cancer

  2. Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

    Recruiting Phase 3 Genmab Started 2026Primary completion 2028-10 NCT07225270

    rinatabart sesutecanbevacizumab FDA EU

    Participants with known breast cancer (BRCA)-mutated (somatic or germline) or homologous recombination deficiency (HRD)-positive ovarian cance…

    BRCA1/2 mutationOvarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC

  3. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    Recruiting Phase 1/2 Genmab Started 2022Primary completion 2027-07 NCT05579366

    rinatabart sesutecancarboplatinbevacizumabpembrolizumaberythromycinitraconazole

    …ncer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (Part A), EGFR-mutated NSCLC (Part B), breast cancer (hormone receptor positive, HER2-negative and triple-negati…

    EGFR exon 19 deletion / L858RBRCA1/2 mutationHigh Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer